NCT06854250View on ClinicalTrials.gov

Prostate Cryoablation Combined with Metronomic Cyclophosphamide for Metastatic Prostate Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

March 1, 2029

Study Completion Date

March 1, 2030

Conditions
Metastatic Prostate Cancer
Interventions
PROCEDURE

Prostate cryoablation

Enrolled patients will receive prostate cryoablation within 6 months of starting androgen deprivation therapy.

DRUG

Cyclophosphamide (CTX)

Enrolled patients will receive cyclophosphamide (50mg daily) one day after prostate cryoablation and continue for a total of six months.

All Listed Sponsors
lead

Sun Yat-sen University

OTHER